Flickr Albums
Novartis is leading the way with a new generation targeted psoriasis treatment: CosentyxTM (secukinumab) the first IL-17A inhibitor with positive CHMP opinion
Novartis Logo

Cosentyx™ (secukinumab) is recommended for approval as first-line systemic* therapy for the treatment of moderate-to-severe plaque psoriasis in adult patients, and is a first-in-class therapy that blocks the protein IL-17A, which is found in high concentrations in psoriasis affected skin1,2

Secukinumab has demonstrated greater efficacy in reducing plaque psoriasis than seen with an existing NICE-recommended treatment1

NICE recognises psoriasis is 'more than just a skin condition', affecting psychological and social wellbeing, and being associated with complex co-morbidities,including arthritis, diabetes and hypertension3–6



*Systemic: treatments or medication travel through the blood stream, allowing them to be carried where they are needed to work

1.           Langley, R. G. et al. Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials. N. Engl. J. Med. 371, 326–38 (2014).

2.           Johansen, C. et al. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br. J. Dermatol. 160, 319–324 (2009).

3.           Takeshita, J. et al. Effect of Psoriasis Severity on Hypertension Control: A Population-Based Study in the United Kingdom. JAMA dermatology 19104, (2014).

4.           Farley, E. & Menter, A. Psoriasis: comorbidities and associations. G. Ital. Dermatol. Venereol. 146, 9–15 (2011).

5.           Gisondi, P. & Girolomoni, G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin. Thromb. Hemost. 35, 313–324 (2009).

6.           NICE. Psoriasis is “more than just a skin condition.” (2014). at Accessed: November 2014


High Definition broadcast quality video is available for download.
Standard-Definition broadcast quality video is available for download in PAL & NTSC.
Streaming quality video is available for download as WMV,Quicktime or FLV.
Production quality audio files are available for download.
Production quality print images are available for download.
YouTube videos are also associated with this article.
Flickr images are also associated with this article.


This content is no longer available.

It may have expired or been deleted.

Related Media


This content is no longer available.

It may have expired or been deleted.

For More Information
Novartis has partnered with TheNewsMarket to provide broadcast-standard video - delivered digitally. To make sure that our assets are available to appropriate audiences, some assets appear locked. These are password protected and can only be accessed by journalists and a select group of users. If you are new to the site, please register. Your information will be verified by our team as quickly as possible. Once approved, you will be sent an email confirming your username and password. If you are an existing user of TheNewsMarket, please contact the Novartis media team for access. You may use non-protected material provided in this section for your personal use or for purposes such as news reporting, teaching, scholarship or research. The assets may not be modified and must display a copyright notice in the name of Novartis (Copyright © Novartis).

The information on these pages was factually accurate on the date of publication. This information remains on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates
Flickr Albums
This is an RSS feed intended to be viewed in newsreader or syndicated to another site